COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,009 Articles (22,627 medRxiv, 8,382 bioRxiv)

Most recent first Previous |  Page 532: Articles 5311-5320  | Next

Durability of immune responses to the booster mRNA vaccination against COVID-19
S Arunachalam, P., Lai, L., Samaha, H., Feng, Y., Hu, M., Hui, H. S.-y., Wali, B., Ellis, M., Huerta, C., Bechnack, K., Bechnack, S., Lee, M., Litvack, M., Losada, C., Grifoni, A., Sette, A., Zarnitsyna, V. I., Rouphael, N., Suthar, M. S., Pulendran, B.
10.1101/2022.12.02.22282921 — Posted: 2022-12-04
Evaluating primary and booster vaccination prioritization strategies for COVID-19 by age and high-contact employment status using data from contact surveys
Roubenoff, E. M., Feehan, D., Mahmud, A. M.
10.1101/2022.12.02.22283040 — Posted: 2022-12-04
The Societal Value of Vaccines: Expert-Based Conceptual Framework and Methods Using COVID-19 Vaccines as A Case Study
Di Fusco, M., Mendes, D., Steuten, L., Bloom, D. E., Drummond, M., Hauck, K., Pearson-Stuttard, J., Power, R., Salisbury, D., Towse, A., Roiz, J., Szabo, G., Yang, J., Marczell, K.
10.1101/2022.12.02.22283046 — Posted: 2022-12-04
Death, Inequality, and the Pandemic in the Nation's Capital
Alva, M., Illa, S. S., Haber, J. R.
10.1101/2022.12.02.22283039 — Posted: 2022-12-04
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines
de Bruyn, G., Wang, J., Purvis, A., Sanchez Ruiz, M., Adhikarla, H., Alvi, S., Bonaparte, M. I., Brune, D., Bueso, A., Canter, R. M., Angeles Ceregido, M., Diemert, D., Finn, A., Forrat, R., Fu, B., Gallais, J., Griffin, P., Grillet, M.-H., Haney, O., Henderson, J. A., Koutsoukos, M., Launay, O., Martinon Torres, F., Masotti, R., Michael, N. L., Park, J., Rivera, D. M., Romanyak, N., Rook, C., Schuerman, L., Sher, L. D., Tavares-Da-Silva Sachin Deshmukh, F., Whittington, A., Chicz, R. M., Gurunathan, S., Savarino, S., Sridhar, S., VAT00002 booster cohorts study team
10.1101/2022.12.02.22282931 — Posted: 2022-12-03
Analysis of the ARTIC V4 and V4.1 SARS-CoV-2 primers and their impact on the detection of Omicron BA.1 and BA.2 lineage defining mutations
Ulhuq, F. R., Barge, M., Falconer, K., Wild, J., Fernandes, G., Gallagher, A., McGinley, S., Sugadol, A., Tariq, M., Maloney, D., Kenicer, J., Dewar, R., Templeton, K., McHugh, M.
10.1101/2022.12.01.22282842 — Posted: 2022-12-03
Evaluating the use of social contact data to produce age-specific forecasts of SARS-CoV-2 incidence
Munday, J. D., Abbott, S., Meakin, S., Funk, S.
10.1101/2022.12.02.22282935 — Posted: 2022-12-03
Associations between area-level health-related social factor indices and risk of acute COVID-19: An EHR-based cohort study from the RECOVER program
Chisolm, D. J., Webb, R., Salamon, K., Schuchard, J., Mendonca, E., Sills, M., Patel, P., Musante, J., Forrest, C. B., Jhaveri, R., Pajor, N. M., Rao, S., Mejias, A., Lee, G. M.
10.1101/2022.12.02.22282944 — Posted: 2022-12-03
Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico
Gonzalez-Montes, J. A., Zaragoza-Jimenez, C. A., Antonio-Villa, N. E., Fermin-Martinez, C. A., Ramirez-Garcia, D., Vargas-Vazquez, A., Gutierrez-Vargas, R. I., Garcia-Rodriguez, G., Lopez-Gatell, H., Valdes-Ferrer, S. I., Bello-Chavolla, O. Y.
10.1101/2022.12.02.22282981 — Posted: 2022-12-03
Battle of Polio eradication in the Western Pacific Region in the transition to COVID-19 endemicity
Mei, R., Kwok, S. L. L., Lau, E. H. Y., Lo, T. H. K., Wu, J. T., Lin, L. K., Leung, K.
10.1101/2022.11.30.22282954 — Posted: 2022-12-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).